{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:03:51Z","timestamp":1790744631396,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["22HA1004"],"award-info":[{"award-number":["22HA1004"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jiac.2023.08.017","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T02:03:31Z","timestamp":1693793011000},"page":"1152-1159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of the predictive accuracy of the physiologically based pharmacokinetic (PBPK) model and population pharmacokinetic (PPK) model of vancomycin in Japanese patients with MRSA infection"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7111-7746","authenticated-orcid":false,"given":"Takumi","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6990-425X","authenticated-orcid":false,"given":"Toshimi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Ebihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5231-8027","authenticated-orcid":false,"given":"Hidefumi","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5659-6507","authenticated-orcid":false,"given":"Yukihiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jiac.2023.08.017_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7326\/0003-4819-97-3-344","article-title":"Vancomycin therapy for methicillin-resistant Staphylococcus aureus","volume":"97","author":"Sorrell","year":"1982","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jiac.2023.08.017_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus Review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.jiac.2023.08.017_bib3","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model\u2010informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jiac.2023.08.017_bib4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/17512433.2018.1501271","article-title":"Precision dosing in clinical medicine: present and future","volume":"11","author":"Polasek","year":"2018","journal-title":"Expet Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jiac.2023.08.017_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","article-title":"Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy","volume":"61","author":"Darwich","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.jiac.2023.08.017_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/cts.12490","article-title":"Precision dosing: public Health need, proposed framework, and anticipated impact","volume":"10","author":"Gonzalez","year":"2017","journal-title":"Clinical and Translational Science"},{"key":"10.1016\/j.jiac.2023.08.017_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/2042098619894147","article-title":"Precision dosing to avoid adverse drug reactions","volume":"10","author":"Polasek","year":"2019","journal-title":"Therapeutic Advances in Drug Safety"},{"issue":"4","key":"10.1016\/j.jiac.2023.08.017_bib8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/cpdd.638","article-title":"Toward dynamic prescribing information: codevelopment of companion model-informed precision dosing tools in drug development","volume":"8","author":"Polasek","year":"2019","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"5","key":"10.1016\/j.jiac.2023.08.017_bib9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future","volume":"101","author":"Darwich","year":"2017","journal-title":"Clin Pharmacol Therapeut"},{"issue":"2","key":"10.1016\/j.jiac.2023.08.017_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/bcp.13119","article-title":"Understanding and applying pharmacometric modelling and simulation in clinical practice and research","volume":"83","author":"Standing","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jiac.2023.08.017_bib11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11095-021-03030-y","article-title":"Performance of area under the concentration-time curve estimations of vancomycin with limited sampling by a newly developed web application","volume":"38","author":"Oda","year":"2021","journal-title":"Pharmaceut Res"},{"issue":"1","key":"10.1016\/j.jiac.2023.08.017_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/antibiotics11010096","article-title":"Validation of vancomycin area under the concentration\u2014time curve estimation by the bayesian approach using one-point samples for predicting clinical outcomes in patients with methicillin-resistant Staphylococcus aureus infections","volume":"11","author":"Ueda","year":"2022","journal-title":"Antibiotics"},{"issue":"6","key":"10.1016\/j.jiac.2023.08.017_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40262-020-00866-2","article-title":"An update on population pharmacokinetic analyses of vancomycin, Part I: in adults","volume":"59","author":"Aljutayli","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.jiac.2023.08.017_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/psp4.12279","article-title":"Using a vancomycin PBPK model in special populations to elucidate case\u2010based clinical PK observations","volume":"7","author":"Emoto","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"10.1016\/j.jiac.2023.08.017_bib15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/psp4.12134","article-title":"Applied concepts in PBPK modeling: how to build a PBPK\/PD model","volume":"5","author":"Kuepfer","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"10.1016\/j.jiac.2023.08.017_bib16","first-page":"150","article-title":"In silico pharmacokinetic study of vancomycin using PBPK modeling and therapeutic drug monitoring","volume":"22","author":"Ferreira","year":"2021","journal-title":"Curr Drug Metabol"},{"issue":"7","key":"10.1016\/j.jiac.2023.08.017_bib17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40262-016-0475-3","article-title":"Development of a physiologically based pharmacokinetic modelling approach to predict the pharmacokinetics of vancomycin in critically ill septic patients","volume":"56","author":"Radke","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.jiac.2023.08.017_bib18","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1038\/psp.2012.3","article-title":"Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling","volume":"1","author":"Huisinga","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.jiac.2023.08.017_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jps.10005","article-title":"Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution","volume":"91","author":"Poulin","year":"2002","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.jiac.2023.08.017_bib20","series-title":"Basic clinical pharmacokinetics","author":"Winter","year":"1994"},{"issue":"2","key":"10.1016\/j.jiac.2023.08.017_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00007691-199804000-00003","article-title":"Population pharmacokinetics of vancomycin in Japanese adult patients","volume":"20","author":"Yasuhara","year":"1998","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.jiac.2023.08.017_bib22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"issue":"10","key":"10.1016\/j.jiac.2023.08.017_bib23","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/bcp.14066","article-title":"An evaluation of the user-friendliness of Bayesian forecasting programs in a clinical setting","volume":"85","author":"Kumar","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.jiac.2023.08.017_bib24","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis: An Official Publication of the Infectious Diseases Society of America"},{"issue":"6","key":"10.1016\/j.jiac.2023.08.017_bib25","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/jac\/dks066","article-title":"Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years","volume":"67","author":"Grace","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.jiac.2023.08.017_bib26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jiac.2019.04.017","article-title":"Evaluation for optimal dosing of vancomycin in patients with different physical types","volume":"25","author":"Hashimoto","year":"2019","journal-title":"J Infect Chemother: Official Journal of the Japan Society of Chemotherapy"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23002039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23002039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:06:50Z","timestamp":1761160010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X23002039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1341321X23002039"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2023.08.017","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the predictive accuracy of the physiologically based pharmacokinetic (PBPK) model and population pharmacokinetic (PPK) model of vancomycin in Japanese patients with MRSA infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2023.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}